07:00 , Sep 3, 1996 |  BioCentury  |  Emerging Company Profile

IntraImmune: The insider's approach

During normal functioning of the human immune system, antibodies generally work outside of cells, chemically marking foreign bodies - such as bacteria or viruses - for later destruction by the host's own disease-fighting white blood...
08:00 , Nov 13, 1995 |  BioCentury  |  Emerging Company Profile

ProScript: A new name and a new direction

Six months ago, a young company, MyoGenics, changed both its name and its direction following its discovery of a new mechanism of action for regulating inflammatory response and cell division. Thomas Maniatis of Harvard University,...
08:00 , Feb 6, 1995 |  BC Week In Review  |  Clinical News

Topical dexchlorpheniramine antihistamine that uses lipid solubility to enhance skin penetration: Began Phase IB/II dose-escalation trial

Arcturus Pharmaceutical Corp. , Woburn, Mass.   Product: Topical dexchlorpheniramine antihistamine that uses lipid solubility to enhance skin penetration   Indication: Treat pruritis (itch) in patients with atopic dermatitis   Status: Began Phase IB/II dose-escalation...
08:00 , Dec 12, 1994 |  BC Week In Review  |  Clinical News

Arcturus regulatory update

The Woburn, Mass., company received notice of allowance for a U.S. patent covering technology that enables the topical delivery of a range of therapeutic amines. The patent descibes formulations of amines that include established GRAS...
08:00 , Nov 14, 1994 |  BC Week In Review  |  Clinical News

Arcturus preclinical data

The Woburn, Mass., company reported animal findings with a topical mixture that optimizes skin concentration of the inhibitor of DNA synthesis, and minimizes its spread to other organs. At the meeting of the American Association...
07:00 , May 23, 1994 |  BC Week In Review  |  Company News

Arcturus deal

The Woburn, Mass., company entered a 10-year agreement with Trans CanaDerm Inc. (Montreal) to develop and commercialize Arcturus' dermatologic products in Canada. Trans CanaDerm, which took an undisclosed equity position in Arcturus, will fund initial...
07:00 , Apr 25, 1994 |  BioCentury  |  Finance

Blech raises more money

Blech raises more money New York investor David Blech continued his fund-raising activities last week, selling 4.5 million shares of Bio-Technology General Corp. to institutional investors at $2.375 on Friday. The price was a 17...
07:00 , Apr 18, 1994 |  BioCentury  |  Finance

Wild week for Blech watchers

The decline in the value of biotechnology shares, and the impact that has had on New York investor David Blech's portfolio, is adding one more negative factor to the gloomy market for initial public offerings....
08:00 , Nov 1, 1993 |  BC Week In Review  |  Clinical News

Dexchlorpheniramine: Began a Phase I trial

Arcturus Pharmaceutical Corp.   Product: Dexchlorpheniramine   Indication: Treatment of pruritis (itch) associated with skin disorders   Status: Began a Phase I trial  ...